Record backlog, margin miss — execution test ahead

Delivered $310M backlog, confirmed 25% YoY in INR and 13.3% in USD

Q1 EBITDA came in at 15.4%, below guidance by 60+ basis points

No independent validation of count; Data/Automation/AI line item grew 9.8% QoQ, consistent with active pipeline

7.7% YoY revenue and 15.0% YoY PAT growth modest; better directionally but not disclosed quantitatively

NHS England old project close and new data modernization projects starting; timing claim not yet validated

40+ AI-led deals closed in Q1 vs. ambient traction in prior calls. Data/Automation/AI line grew 9.8% QoQ. Management created internal customer AI maturity model (Level 0–5) to drive expansion; significant upgrade in pipeline focus.

12-month backlog 25% YoY, 13.3% in USD terms. Consistent with prior 3–4 quarters of order-book growth; now converting to revenue (5% QoQ, 7.7% YoY). $25M Salesforce Agentforce deal and large Middle East Healthcare deal show deal-size expansion.

Prior guidance: 16.0–16.1%. Delivered: 15.4%. Miss driven by Middle East headwinds (bench cost, collection delays, provision ₹31 Cr income-tax impact), regulatory costs UK, and healthcare customer mix. Management declined to reaffirm or reissue FY27 margin guidance.

NHS England (top customer) ramped down old project; new data modernization project starting. This was flagged in prior call; timing gap now materializing. Top 5 customers declined 12% YoY as a result. Expected to reverse Q2+.

In prior call, Middle East was stable. Q1 saw geopolitical crisis (West Asia), collection delays (₹2.5M pushout), bench costs, and heightened uncertainty on deal ramp-ups. Management now cautious; despite large order wins, predictability low. Headwind likely to persist near-term.

New costs announced: ESOP $400-500k/quarter from Q2 (~25 bps impact), increments planned Q2. No steady-state margin guidance provided. Prior guidance implied 16%+ sustainable; now uncertain. Management focused on cost efficiencies to mitigate but offered no quantified offset.

FCA already ramping (shown in banking growth, more in Q2). HADES renewal, steady revenue only. North America $25M deal ramping H2 FY27, not before.

NHS England (top customer) transitioned from old project closure to new data modernization ramp. Timing gap Q1; expected to normalize Q2+.

Subcon stable 18.5% of revenue. ESOP from Q2: $400-500k/quarter (~25 bps impact).

TCV growing well. $25M North America deal is 5-year example. Total order book (not just 12-month backlog) growing healthily, though not disclosed numerically.

No, discounts 15–25% range in most cases; some 50% in competitive pockets. Aggressive competition but manageable. Fixed-bid/outcome contracts should deliver better margins.

UK Healthcare will ramp Q2 onwards. US Healthcare Life Sciences expected H2. Middle East Healthcare ramping but geopolitical uncertainty slows timing.

Yes, but pipeline strong, funnel quality high, large deal opportunities increasing. These are well-qualified with serious winning chances.

Healthcare deal won Q1, planned immediate ramp. Geopolitical uncertainty affects timing; if stabilizes, margins normalize. Currently flat outlook expected.

Currently at 15.4%; ESOP and increments will impact. We'll not be able to provide guidance at this point in time. Working on cost efficiencies to mitigate.

FY27 should be better than FY26. North America needs H2 to inflect. Middle East uncertain. AI competition is headwind; must protect turf on existing customers. Directionally positive but cautious.

Directional, not numeric. Prior FY26 baseline not stated; no quantified FY27 revenue target or CAGR provided. Order backlog 25% YoY growth and AI pipeline strong, but no explicit revenue number committed.

Prior guidance 16.0–16.1% missed (15.4% delivered). ESOP $400-500k/qtr from Q2. Increments Q2. Working on cost efficiencies to offset, but no new margin target disclosed. Explicitly declined to provide steady-state guidance.

West Asia crisis creating volatility. Large Healthcare deal won Q1 but ramp-up timing uncertain. Collection delays (₹2.5M pushout early July), bench provisioning, and client readiness unpredictable.

Top customer (NHS England, UK Healthcare) transitioned from old project close to new data modernization project ramp. Top 5 customers declined 12% YoY, 4% QoQ. Timing gap in Q1; recovery expected Q2+ but revenue lumpy.

Q1 EBITDA 15.4% vs. prior 16.0–16.1% guidance, miss by 60+ bps. Middle East provisions (₹31 Cr tax impact FY22-23), regulatory costs UK, collection impact. ESOP ($400-500k/qtr from Q2), increments Q2, and regulatory costs expected to continue weighing. No steady-state margin guidance provided.

North America grew only 2% QoQ in constant currency despite $25M deal win. Business needs $28-30M/qtr run rate to deliver mid-teens margins. Management expects inflection by H2 but unproven. Currently still investing in sales/marketing, margins subdued.

Aggressive price competition on both new wins and renewals. Discounts 15–25% common; some cases 50% (though Mastek claims restraint vs. peers). Net new business coming at more aggressive pricing. Risk of margin compression on large deals if discounting escalates.